Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 188

The DOI matches its Crossref record.

Efficacy and Safety of Intermittent Intravenous Outpatient Administration of Levosimendan in Patients With Advanced Heart Failure: The LION-HEART Multicentre Randomised Trial

Open access
Comín-Colet, Josep, Manito, Nicolás, Segovia-Cubero, Javier, Delgado, Juan, García Pinilla, José Manuel, Almenar, Luis, Crespo-Leiro, María G., Sionis, Alessandro, Blasco, Teresa, Pascual-Figal, Domingo, Gonzalez-Vilchez, Francisco, Lambert-Rodríguez, José Luis, Grau, María, Bruguera, Jordi·2018·European Journal of Heart Failure

Abstract

Aims: The LION-HEART study was a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial evaluating the efficacy and safety of intravenous administration of intermittent doses of levosimendan in outpatients with advanced chronic heart failure. Methods and results: Sixty-nine patients from 12 centres were randomly assigned at a 2:1 ratio to levosimendan or placebo groups, receiving treatment by a 6-hour intravenous infusion (0.2 μg/kg/min without bolus) every 2 weeks for 12 weeks. The primary endpoint was the effect on serum concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) throughout the treatment period in comparison with placebo. Secondary endpoints included evaluation of safety, clinical events and health-related quality of life (HRQoL). The area under the curve (AUC, pg.day/mL) of the levels of NT-proBNP over time for patients who received levosimendan was significantly lower than for the placebo group (344 × 103 [95% Confidence Interval (CI) 283 × 103−404 × 103] vs. 535 × 103 [443 × 103−626 × 103], p = 0.003). In comparison with the placebo group, the patients on levosimendan experienced a reduction in the rate of heart failure hospitalisation (hazard ratio 0.25; 95% CI 0.11–0.56; P = 0.001). Patients on levosimendan were less likely to experience a clinically significant decline in HRQoL over time (P = 0.022). Adverse event rates were similar in the two treatment groups. Conclusions: In this small pilot study, intermittent administration of levosimendan to ambulatory patients with advanced systolic heart failure reduced plasma concentrations of NT-proBNP, worsening of HRQoL and hospitalisation for heart failure. The efficacy and safety of this intervention should be confirmed in larger trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ejhf.1145

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 188

Metadata

Authors
Comín-Colet, J., Manito, N., Segovia-Cubero, J., Delgado, J., García Pinilla, J. M., Almenar, L., Crespo-Leiro, M. G., Sionis, A., Blasco, T., Pascual-Figal, D., Gonzalez-Vilchez, F., Lambert-Rodríguez, J. L., Grau, M., & Bruguera, J.
Venue
European Journal of Heart Failure
Published
2018-02-06
Volume
20
Issue
7
Pages
1128-1136
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2791808508
Cited by
188
References
0
FWCI
13.42
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Intermittent Intravenous Outpatient Administration of Levosimendan in Patients With Advanced Heart Failure: The LION-HEART Multicentre Randomised Trial. https://app.cochat.ai/papers/10.1002/ejhf.1145
The paper
Comín-Colet, J., Manito, N., Segovia-Cubero, J., Delgado, J., García Pinilla, J. M., Almenar, L., Crespo-Leiro, M. G., Sionis, A., Blasco, T., Pascual-Figal, D., Gonzalez-Vilchez, F., Lambert-Rodríguez, J. L., Grau, M., & Bruguera, J. (2018). Efficacy and Safety of Intermittent Intravenous Outpatient Administration of Levosimendan in Patients With Advanced Heart Failure: The LION-HEART Multicentre Randomised Trial. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.1145

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.